Figure 7. Immunofluorescence staining of the lumbar spinal cord section of SOD1G93A transgenic mouse transplanted with F3.Olig2-Shh cells.
Image credit: Lee, et.al. 2014 under CC BY license

Funding Opportunities

To submit any new grant opportunities for this list, please email ALSgrants@prize4life.org. List the sponsor name, amount, due date, and contact information.

 


 

Current Funding Opportunities:


NEW! Rapid Response: Canada 2018
Sponsor: Weston Brain Institute
Description: This program provides seed funding for high-risk, high-reward, translational research projects on neurodegenerative diseases of aging including FTD.   A maximum of $200,000 over up to 18 months per project. Principal applicants must be researchers working in Canada at least 30% of the time above the level of Postdoctoral Fellow, and be affiliated with a Canada Revenue Agency-qualified donee institution located in Canada. Applications are expected to begin to be accepted in February 2018.
Deadline: Letter of Intent due by April 2018.



NEW! Research Grants
Sponsor: Fight MND
Description: These grants support the preclinical research, development, and assessment of therapeutics for MND through to (and including) completion of Phase I clinical trials. These grants are each awarded with an offer of up to AUD $1,000,000 in support available for 3-year projects. Researchers globally are invited to apply.
Deadline: Application due by April 1, 2018.



Clinical Scientist Development Award
Sponsor: Doris Duke Charitable Foundation
Description: The Doris Duke Clinical Scientist Development Award provides grants to junior physician scientists in any disease area to facilitate their transition to independent clinical research careers.
Deadline: Pre-Proposal due by December 1, 2017.



MDA Venture Philanthropy Program
Sponsor: Muscular Dystrophy Association
Description: MDA’s MVP program is exclusively focused on funding the discovery and clinical application of treatments and cures for neuromuscular diseases. The diseases funded include ALS. MVP funds projects from proof-of-principle studies through phase 2 trials. The maximum award is  $1M USD for preclinical studies, $3M USD for early clinical studies and $500,000 USD for R&D.
Deadline: Letter of Intent due by December 1, 2017.



Technological Innovations in Neuroscience Awards
Sponsor: The McKnight Foundation
Description: This program seeks to advance and enlarge the range of technologies available to the neurosciences. These awards support scientists working on new and unusual approaches to understanding brain function. Technology may take any form, from biochemical tools to instruments to software and mathematical approaches. The fund is especially interested in how the technology may be used or adapted to monitor, manipulate, analyze, or model brain function at any level, from the molecular to the entire organism. Awards provide up to $100,000 per year for two years. Research based primarily on existing techniques will not be considered.
Deadline: Letter of Intent due by December 4, 2017.



NeuroNEXT Clinical Trials
Sponsor: NINDS
Description: This FOA encourages applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing a future trial, for biomarker validation studies, or for proof of mechanism clinical studies. Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. Following peer review, NINDS will prioritize and order trials that are given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.
Deadline: Application due by December 6, 2017.



Transformational Research: Canada 2018
Sponsor: Weston Brain Institute
Description: This program funds transformative, novel, high-risk, high-reward translational research projects with excellent preliminary data aimed at accelerating the development of therapies for neurodegenerative diseases of aging including FTD. A maximum of $1,500,000 over up to 3 years per project. PIs must be at or above the level of Assistant Professor or equivalent, work in Canada at least 30% of the time, and be affiliated with a CRA-qualified institution.
Deadline: Letter of Intent due by December 7, 2017.



Altman Award in Developmental Neuroscience (Worldwide)
Sponsor: Japan Neuroscience Society
Description: This award focuses on developmental neuroscience at the cellular and/or tissue level. Projects recognized include adult neurogenesis and its biological significance and its changes resulting from aging and diseases. The award is $10,000 USD. Researchers worldwide are invited to apply. Applicants must hold a PhD for no more than 20 years. Applications accepted beginning November 1, 2017.
Deadline: Application due by January 31, 2018.



High Impact Neuroscience Research Resource Grants
Sponsor: NINDS
Description: This funding opportunity announcement (FOA) supports high impact efforts to make resources available to neuroscience researchers. Projects should engage in one or more of the following activities: facilitating access to cutting edge reagents or techniques, dissemination of resources to new user groups, or innovative approaches to increase the scale/efficiency of resource production and delivery. Applications focused primarily on technology or software development are not responsive to this FOA, as the focus is on dissemination or provision of resources. Use of existing technologies to develop new reagents or genetic lines of significant value to the research community may be appropriate. Projects should address compelling needs of broad communities of neuroscience researchers or should offer unique services that otherwise would be unavailable.
Deadline: Application due by February 9, 2018.



Rapid Response: Ireland, Netherlands, UK 2018
Sponsor: Weston Brain Institute
Description: Provides seed funding up to £175,000 per project for over up to 2 years for novel, high-risk, high-reward translational research projects that accelerate the development of therapeutics for neurodegenerative diseases of aging including FTD based in Europe. Applications will begin to be accepted in January 2018.
Deadline: Application due by April 2018.



ADDF NIH Scored Unfunded Grants (includes FTD)
Sponsor: Alzheimer's Drug Discovery Foundation
Description: This request for proposals supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities. This includes frontotemporal dementias.
Deadline: Applications are accepted on a rolling basis..



CLIN 2: Partnering Opportunity for Clinical Trial Stage Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity for promising stem cell-based projects to accelerate the completion of a clinical trial for a stem cell treatment that addresses an unmet medical need.
Deadline: Last business day of each month.



CLIN 3: Partnering Opportunity for Supplemental Accelerating Activities
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to support new activities on active CIRM-funded development projects that will significantly accelerate development of the proposed treatment or increase the likelihood of success.
Deadline: Last business day of each month.



Catalyst Grant: New Genes for Rare Diseases
Sponsor: Rare Diseases Models and Mechanisms Network
Description: On behalf of the Clinical Advisory Committee of the Rare Diseases: Models and Mechanisms Network, the Co-Chairs would like to invite applications from clinicians and clinician scientists who have discovered novel genes in patients with rare diseases and wish to collaborate with a model organism investigator who is able to carry out functional analysis on an orthologous gene in a model system. A maximum of $25,000 CAD will be awarded. Applications may be submitted by any investigator associated with a Canadian Institution.
Deadline: Applications will be accepted on a rolling basis.



Clin1: Partnering Opportunity for Late Stage Preclinical Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity for promising stem cell-based projects to accelerate the completion of preclinical activities necessary to attain an active IND or IDE with the FDA and to initiate start-up activities of the proposed clinical trial. CIRM expects projects under this program to advance rapidly into the clinic and to be accomplished within two years unless adequately justified.
Deadline: Last business day of each month.



Early Phase Clinical Trials, Canada (Includes FTD)
Sponsor: Weston Brain Institute
Description: The Early Phase Clinical Trials Canada program provides funding to support clinical trials and/or clinical trial sub-studies that could accelerate the development of therapeutics for neurodegenerative disease aging, including FTD. Eligible principal investigators must be at or above the level of Assistant Professor or equivalent, and be affiliated with a CRA-qualified institution located in Canada. A maximum of $1,500,000 per project over up to 4 years.
Deadline: Applications will be accepted on a rolling basis.



Identify, Analyze and Evaluate Potential Risk Factors for ALS
Sponsor: CDC
Description: The purpose of this funding opportunity announcement (FOA) is to allow for investigator initiated research that will further the understanding of potential risk factors for ALS, while supporting the National ALS Registry's mission. Maximum award is $400,000 USD. Note: This is a forecasted opportunity.
Deadline: February 16, 2018 (estimated).



NIH TRND Program and NIH BrIDGs Program
Sponsor: NIH National Center for Advancing Translational Sciences (NCATS)
Description: NCATS is now accepting proposals on a rolling basis to collaborate with Bridging Interventional Development Gaps (BrIDGs) and Therapeutics for Rare and Neglected Diseases (TRND) program scientists. Click here to apply.
Deadline: Now accepting rolling applications.



NINDS Training and Career Development Awards
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description: NINDS offers a wide range of training and career development funding opportunities including pre-doctoral fellowships, post-doctoral fellowships, mentored career development awards, institutional programs, independent scientists awards, clinical research awards and more. All programs are open to researchers focusing on the study of ALS and related conditions.
Deadline: Varies, see individual program for details.



NeuroNEXT Infrastructure Resource Access
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description:

This funding opportunity announcement (FOA) encourages proposals for biomarker validation trials or exploratory clinical trials of drugs, biologics, surgical therapies or devices that may contribute to the justification for and provide the data required to design a future trial to confirm efficacy (i.e., a Phase III trial) in the treatment of neurologic disease. Proposals for drugs or biologics should provide compelling scientific evidence that the investigational agent proposed for study will reach/act upon the designated target or that its mechanism of action is such that it will be of benefit in ameliorating a specific aspect of the disease.

Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.


Deadline: Now accepting rolling applications.



Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail